Eprosartan mesylate/Hydrochlorothiazide

依普沙坦甲磺酸盐/氢氯噻嗪

Report date: 2022/08/16 20:00:19

Base Information

Drug NameEprosartan mesylate/Hydrochlorothiazide
Drug Alias NameEprosartan mesylate - hydrochlorothiazide mixt氢氯噻嗪/依普沙坦甲磺酸盐Hydrochlorothiazide/Eprosartan mesylateTeveten HCT
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsThiazide-sensitive sodium-chloride cotransporter inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2001/11/01
Country/TerritoryUnited States
CombinationsYes Eprosartan MesylateHydrochlorothiazide
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbvie Inc
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeC09DA02
Related LinksKEGG